R&D | January 21, 2026
Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
India in the Changing Landscape of Life-Sciences Research & Development
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
Subscribe To Our Newsletter & Stay Updated
